Anna P Durbin

Anna P Durbin

UNVERIFIED PROFILE

Are you Anna P Durbin?   Register this Author

Register author
Anna P Durbin

Anna P Durbin

Publications by authors named "Anna P Durbin"

Are you Anna P Durbin?   Register this Author

71Publications

1410Reads

44Profile Views

What is the prospect of a safe and effective dengue vaccine for travellers?

J Travel Med 2019 Sep;26(6)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Global Dengue and Aedes-Transmitted Diseases Consortium (GDAC).

View Article

Download full-text PDF

Source
https://academic.oup.com/jtm/advance-article/doi/10.1093/jtm
Publisher Site
http://dx.doi.org/10.1093/jtm/tay153DOI Listing
September 2019

Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue.

ACS Infect Dis 2018 12 5;4(12):1705-1717. Epub 2018 Nov 5.

Molecular and Translational Sciences Division , U.S. Army Medical Research Institute of Infectious Diseases , 1425 Porter Street , Frederick , Maryland 21702 , United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acsinfecdis.8b00185
Publisher Site
http://dx.doi.org/10.1021/acsinfecdis.8b00185DOI Listing
December 2018

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.

Cell Rep 2018 10;25(5):1214-1224

Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, Chapel Hill, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183156
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.10.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226424PMC
October 2018

Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination.

Influenza Other Respir Viruses 2018 03 4;12(2):202-210. Epub 2018 Jan 4.

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/irv.12509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820426PMC
March 2018

Zika Vaccines: Role for Controlled Human Infection.

J Infect Dis 2017 12;216(suppl_10):S971-S975

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jix491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853527PMC
December 2017

Dengue vaccines: implications for dengue control.

Curr Opin Infect Dis 2017 Oct;30(5):449-454

aDivision of Infectious Disease, Johns Hopkins School of Medicine bDepartment of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QCO.0000000000000394DOI Listing
October 2017

Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity.

Clin Vaccine Immunol 2017 Apr 5;24(4). Epub 2017 Apr 5.

Molecular and Translational Sciences Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/CVI.00036-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382833PMC
April 2017

Dengue Antibody and Zika: Friend or Foe?

Authors:
Anna P Durbin

Trends Immunol 2016 10 3;37(10):635-636. Epub 2016 Sep 3.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2016.08.006DOI Listing
October 2016

Vaccine Development for Zika Virus-Timelines and Strategies.

Authors:
Anna P Durbin

Semin Reprod Med 2016 09 8;34(5):299-304. Epub 2016 Sep 8.

Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0036-1592070DOI Listing
September 2016

A Dengue Vaccine.

Authors:
Anna P Durbin

Cell 2016 Jun;166(1)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.06.036DOI Listing
June 2016

Dengue human infection models to advance dengue vaccine development.

Vaccine 2015 Dec 28;33(50):7075-82. Epub 2015 Sep 28.

Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, MD 21205, United States; Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2015.09.052DOI Listing
December 2015

WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development.

Vaccine 2015 Oct 27. Epub 2015 Oct 27.

Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, MD 21205, USA; Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2015.09.113DOI Listing
October 2015

The dengue vaccine pipeline: Implications for the future of dengue control.

Vaccine 2015 Jun 16;33(29):3293-8. Epub 2015 May 16.

Center for Inference and Dynamics of Infectious Diseases, Seattle, WA, USA; Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2015.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470297PMC
June 2015

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

PLoS Pathog 2013 5;9(12):e1003761. Epub 2013 Dec 5.

Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1003761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857832PMC
September 2014

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

Vaccine 2013 Nov 19;31(48):5772-7. Epub 2013 Aug 19.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2013.07.064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833717PMC
November 2013

Response to Ruiz-Alejo et al.

J Infect Dis 2013 Oct 11;208(7):1184. Epub 2013 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jit298DOI Listing
October 2013

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Vaccine 2013 Jul 2;31(33):3347-52. Epub 2013 Jun 2.

University of Vermont College of Medicine, Vaccine Testing Center and Unit of Infectious Diseases, 95 Carrigan Drive, Stafford Hall 110, Burlington, VT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2013.05.075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777849PMC
July 2013

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.

PLoS One 2012 4;7(10):e46094. Epub 2012 Oct 4.

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH), Rockville, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046094PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464250PMC
April 2013

Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Virology 2013 Apr 26;439(1):34-41. Epub 2013 Feb 26.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.virol.2013.01.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622939PMC
April 2013

The dengue human challenge model: has the time come to accept this challenge?

J Infect Dis 2013 Mar 5;207(5):697-9. Epub 2012 Dec 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jis749DOI Listing
March 2013

Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.

PLoS Negl Trop Dis 2012 17;6(7):e1742. Epub 2012 Jul 17.

Vaccine Testing Center and Unit of Infectious Diseases, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0001742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398956PMC
November 2012

Next-generation dengue vaccines: novel strategies currently under development.

Viruses 2011 10 26;3(10):1800-14. Epub 2011 Sep 26.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Room 251, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v3101800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205382PMC
October 2011

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Vaccine 2011 Sep 21;29(42):7242-50. Epub 2011 Jul 21.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2011.07.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170437PMC
September 2011

Decay and persistence of maternal dengue antibodies among infants in Bangkok.

Am J Trop Med Hyg 2011 Aug;85(2):355-62

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.2011.11-0125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144837PMC
August 2011

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

PLoS Negl Trop Dis 2011 Aug 2;5(8):e1267. Epub 2011 Aug 2.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0001267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149013PMC
August 2011

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

PLoS Pathog 2011 Jun 30;7(6):e1002111. Epub 2011 Jun 30.

Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1002111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128118PMC
June 2011

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

J Infect Dis 2011 Feb 14;203(3):327-34. Epub 2010 Dec 14.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiq059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071099PMC
February 2011

Dengue vaccine candidates in development.

Curr Top Microbiol Immunol 2010 ;338:129-43

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-02215-9_10DOI Listing
January 2010

Targeted mutagenesis as a rational approach to dengue virus vaccine development.

Curr Top Microbiol Immunol 2010 ;338:145-58

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892-3203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-02215-9_11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405492PMC
January 2010

HIV-1 evolution following transmission to an HLA-B*5801-positive patient.

J Infect Dis 2009 Dec;200(12):1820-4

Department of Medicine, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/648377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779566PMC
December 2009

Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system.

Vaccine 2009 Oct 25;27(44):6143-7. Epub 2009 Aug 25.

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.08.024DOI Listing
October 2009

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Vaccine 2009 Jun 15;27(31):4104-9. Epub 2009 May 15.

Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.04.077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722923PMC
June 2009

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

Am J Trop Med Hyg 2008 Nov;79(5):678-84

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590927PMC
November 2008

Antigenic relationships between sylvatic and endemic dengue viruses.

Am J Trop Med Hyg 2008 Jul;79(1):128-32

Center for Biodefense and Emerging Infectious Diseases, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555-0609, USA.

View Article

Download full-text PDF

Source
July 2008

Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.

PLoS Pathog 2008 May 9;4(5):e1000060. Epub 2008 May 9.

Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1000060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330159PMC
May 2008

Prospects for a dengue virus vaccine.

Nat Rev Microbiol 2007 Jul;5(7):518-28

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrmicro1690DOI Listing
July 2007

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

Hum Vaccin 2006 Nov-Dec;2(6):255-60. Epub 2006 Nov 5.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.2.6.3494DOI Listing
February 2007

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

Hum Vaccin 2006 Jul-Aug;2(4):167-73. Epub 2006 Jul 24.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.2.4.2944DOI Listing
October 2006

Development of a live attenuated dengue virus vaccine using reverse genetics.

Viral Immunol 2006 ;19(1):10-32

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892-8133, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/vim.2006.19.10DOI Listing
July 2006

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Vaccine 2005 May;23(24):3131-8

Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2004.12.019DOI Listing
May 2005

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

J Infect Dis 2005 Mar 27;191(5):710-8. Epub 2005 Jan 27.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/427780DOI Listing
March 2005

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.

Clin Infect Dis 2003 Dec 20;37(12):1668-77. Epub 2003 Nov 20.

Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/379775DOI Listing
December 2003